Clinical Trial Update: Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating durvalumab with surufatinib as maintenance therapy in advanced biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: China Medical University, China | Conditions: Biliary Tract Cancer | Phase 1, Phase 2 | Status: UNKNOWN